

January 30, 2020

To

| | |
|--|--|
| BSE Limited Department of Corporate Services Listing Department P J Towers, Dalal Street, Mumbai - 400001 <i>Scrip Code: 542367</i> | National Stock Exchange of India Limited Listing Department, Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 <i>Scrip Symbol: XELPMOC</i> |
|--|--|

Dear Sir/Madam,

Sub: Intimation under Regulation 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In accordance with Regulation 47(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), please find enclosed herewith copy of advertisement giving notice for scheduling a meeting of Board of Directors of the Company pursuant to Regulation 29 of SEBI LODR.

The above mentioned advertisement is published in The Financial Express (English Newspaper) & Hosadigantha (Kannada Newspaper) on January 30, 2020.

The same has also been uploaded on the Company's website which may be viewed at <https://www.xelpmoc.in/investorrelations>.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Xelpmoc Design and Tech Limited



Vaishali Kondbhar
Company Secretary

Encl: As above



CHANDRA BHAGAT PHARMA LIMITED
 (This is only an advertisement for information purpose and is not a prospectus announcement.)
 CIN: U24230MH2003PLC139534

Our Company was incorporated as "Chandra Bhagat Pharma Private Limited" at Mumbai on March 10, 2003, under the provisions of the Companies Act, 1956 vide Certificate of Incorporation issued by Assistant Registrar of Companies, Maharashtra, Mumbai. Consequent upon the conversion of our Company from Private Limited Company to Public Limited Company, the name of our Company was changed to "Chandra Bhagat Pharma Limited" and fresh Certificate of Incorporation consequent upon the conversion from Private Limited Company to Public Limited Company dated March 20, 2019 was issued by the Registrar of Companies, RoC - Mumbai. For details of change in name and registered office of our Company, please refer to chapter titled "History And Corporate Matters" beginning on Page no. 105 of the Prospectus.

Registered Office: 323-F Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East) Mumbai- 400019; Tel No.: +91 22 2414 6154; Website: www.cbpharma.com; E-Mail: compliance@cbpharma.net; Company Secretary and Compliance Officer: Ms. Payal Bansal

PROMOTERS OF THE COMPANY: MR. HEMANT CHANDRAVADAN BHAGAT AND MR. PRANAV HEMANT BHAGAT

THE ISSUE

PUBLIC ISSUE OF 2000000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH OF CHANDRA BHAGAT PHARMA LIMITED ("CBC" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 51 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹41 PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 1020.00 LAKH ("THE ISSUE"), OF WHICH 100000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH FOR CASH AT A PRICE OF ₹ 51 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 41 PER EQUITY SHARE AGGREGATING TO ₹ 51.00 LAKH WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 1900000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT A PRICE OF ₹ 51 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 41 PER EQUITY SHARE AGGREGATING TO ₹ 969.00 LAKH IS HEREIN REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.51% AND 25.18% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THIS ISSUE IS BEING IN TERMS OF CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 AS AMENDED FROM TIME TO TIME

For further details see "TERMS OF THE ISSUE" beginning on page no. 196 of the Prospectus.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10 EACH AND THE ISSUE PRICE IS ₹51 (INCLUDING PREMIUM OF ₹41 PER EQUITY SHARE). THE ISSUE PRICE IS 5.1 TIMES OF THE FACE VALUE.

ISSUE OPENS ON : FRIDAY, JANUARY 31, 2020

ISSUE CLOSES ON : THURSDAY, FEBRUARY 06, 2020

**MINIMUM LOT SIZE : 2000 EQUITY SHARES FOR RETAIL INDIVIDUAL INVESTORS
 4000 EQUITY SHARES AND IN MULTIPLES OF 2000 EQUITY SHARES THEREAFTER FOR HNI/QIB CATEGORY**

ASBA* Simple, Safe, Smart way of Application - Make use of it!!! Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. Investors can avail the same. For further details read section on ASBA below. Mandatory in Public Issues from January 01, 2016. No Cheques will be accepted.

UPI UPIN AVAILABLE IN ASBA FOR RETAIL INDIVIDUAL INVESTORS. For Details on the ASBA and UPI process, please refer to the details given in ASBA form and Abridge Prospectus and also please refer to the section "Issue Procedure" beginning on page no. 203 of Prospectus. The process is also available on the website of BSE Limited (www.bseindia.com) in General Information Document. List of Banks supporting UPI is also available on the website of SEBI (www.sebi.gov.in)

IN TERMS OF THE SEBI CIRCULAR NO. CIR/CFD/POLICYCELL/11/2015, DATED NOVEMBER 10, 2015 AND THE ALL POTENTIAL INVESTORS SHALL PARTICIPATE IN THE ISSUE ONLY THROUGH AN APPLICATION SUPPORTED BY BLOCKED AMOUNT ("ASBA") PROCESS PROVIDING DETAILS ABOUT THE BANK ACCOUNT WHICH WILL BE BLOCKED BY THE SELF-CERTIFIED SYNDICATE BANKS ("SCSBS") FOR THE SAME. FURTHER PURSUANT TO SEBI CIRCULAR BEARING NO. SEBI/HO/CFD/DIL2/CIR/P/2019/76 DATED JUNE 28, 2019, FOR IMPLEMENTATION OF PHASE II FOR UPI FACILITY, WHICH IS EFFECTIVE FROM JULY 01, 2019, ALL POTENTIAL BIDDERS (EXCEPT ANCHOR INVESTORS) ARE REQUIRED TO MANDATORILY UTILIZE THE APPLICATION SUPPORTED BY BLOCKED AMOUNT ("ASBA") PROCESS PROVIDING DETAILS OF THEIR RESPECTIVE ASBA ACCOUNTS OR UPI ID (IN CASE OF RIIS), IN WHICH THE CORRESPONDING APPLICATION AMOUNTS WILL BE BLOCKED BY THE SCSBS OR UNDER THE UPI MECHANISM, AS APPLICABLE.

FOR DETAILS IN THIS REGARD, SPECIFIC ATTENTION IS INVITED TO "ISSUE PROCEDURE" ON PAGE NO. 203 OF THE PROSPECTUS. IN CASE OF DELAY, IF ANY IN UNBLOCKING/REFUND THE FUND, OUR COMPANY SHALL PAY INTEREST ON THE APPLICATION MONEY AT THE RATE OF 15% PER ANNUM FOR THE PERIOD OF DELAY.

Information under Section 30 of the Companies Act, 2013:
 The information regarding the content of Memorandum of Association of our Company as regards Main objects are available on page no. 108 and 109 of Prospectus of the Company. The Liability of the Members is limited. Our Authorized Share Capital comprises of 8500000 Equity Shares of ₹ 10/- each aggregating to ₹ 850.00 Lakh. The present issued, subscribed and paid up share capital comprises of 5545056 Equity Shares of ₹ 10/- each aggregating to ₹ 554.51 Lakh. We are proposing to issue 2000000 Equity Shares of ₹ 10/- each in terms of the Prospectus dated January 23, 2020 at a price of ₹ 51/- per share including premium of ₹ 41/- per equity share. The Names of signatories to the Memorandum of Association of our Company at the time of Incorporation and number of shares subscribed by them is as follows:

| Sr. No. | Name of Signatories | No. of Equity Shares subscribed (Face Value ₹10/- each) |
|---------|---|---|
| 1. | Late Mr. Chandravadan Chhotatala Bhagat | 5,000 |
| 2. | Mr. Hemant Chandravadan Bhagat | 5,000 |
| | TOTAL | 10,000 |

| Sr. No. | Name of Signatories | No. of Shareholders | No. of Share held | % |
|---------|------------------------------|---------------------|-------------------|---------------|
| 1. | Promoters and Promoter Group | 10 | 5313056 | 95.82 |
| 2. | Public | 42 | 232000 | 4.18 |
| | TOTAL | 52 | 5545056 | 100.00 |

PROPOSED LISTING

The Equity Shares offered through the Prospectus are proposed to be listed on SME Platform of BSE Limited. In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time, our Company has received in principle approval letter dated January 17, 2020 from BSE Limited ("BSE") for using its name in this offer document for listing our shares on the SME Platform of BSE. For the purpose of this Issue, the designated Stock Exchange will be the BSE Limited.

DISCLAIMER CLAUSE OF THE SECURITIES AND EXCHANGE BOARD OF INDIA

Since the Issue is being made in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, the Draft Offer Document had not been filed with SEBI. In terms of the SEBI (ICDR) Regulations, 2018, SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However investors may refer full text of the Disclaimer Clause of SEBI beginning on page no. 188 of the Prospectus.

DISCLAIMER CLAUSE OF THE BSE LIMITED

It is to be distinctly understood that the permission given by BSE Limited ("BSE") should not in any way be deemed or construed that the contents of the Prospectus or the price at which the equity shares are offered has been cleared, solicited or approved by BSE, nor does it certify the correctness, accuracy or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the Disclaimer clause pertaining to BSE appearing on the page no. 188-189 of the Prospectus.

| LEAD MANAGER TO THE ISSUE | REGISTRAR TO THE ISSUE | COMPANY SECRETARY & COMPLIANCE OFFICER |
|--|---|---|
| BEELINE BEELINE BROKING LIMITED SEBI Registration Number: INM000012546 Address: 807, Phoenix Tower, Opp. New Girish Cold Drinks, Near Vijay Cross Roads, Navrangpura, Ahmedabad-380009 Telephone Number: +91 79 4840 5357 Email Id: mb@beelinebroking.com Investors Grievance Id: ig@beelinebroking.com Website: www.beelinebroking.com Contact Person: Mrs. Khushbu Shah CIN: U51900GJ2014PLC080598 | LINK Intime LINK INTIME INDIA PRIVATE LIMITED SEBI Registration Number: INR000004058 Address: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai - 400 083, Maharashtra Tel. Number: +912249186200; Email Id: cbipl.ip@linkintime.co.in Investors Grievance Id: cbipl.ip@linkintime.co.in Website: www.linkintime.co.in Contact Person: Ms. Shanti Gopalakrishnan CIN: U67190MH1999PTC118368 | Ms. Payal Bansal CHANDRA BHAGAT PHARMA LIMITED Registered Office: 323-F, Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East) Mumbai-400019. Telephone: +91 22 2414 6154 Website: www.cbpharma.com E-Mail: compliance@cbpharma.net CIN: U24230MH2003PLC139534 Investors may contact our Company Secretary and Compliance Officer or the Registrar to the Issue in case of any pre-issue or IPO related grievance, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary accounts, non-credit of refund orders and non-credit of funds by electronic mode. |

CREDIT RATING: As this is an issue of Equity Shares there is no credit rating for this Issue.

DEBENTURE TRUSTEES: As this is an issue of Equity Shares, the appointment of Debenture Trustees is not required.

IPO GRADING: Since the Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, there is no requirement of appointing an IPO Grading agency.

BASIS OF ISSUE PRICE: The Issue Price is determined by Company in consultation with the Lead Manager. The financial data presented in section titled "BASIS FOR ISSUE PRICE" on page 68 of the Prospectus are based on Company's Restated Financial Statements. Investors should also refer to the sections/chapters titled "RISK FACTORS" and "RESTATED FINANCIAL INFORMATION" on page no. 15 and 127 respectively of Prospectus to get more informed view before making the investment decision.

RISK TO INVESTORS: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the section titled "RISK FACTORS" beginning on page no. 15 of the Prospectus.

AVAILABILITY OF APPLICATION FORMS: Application Forms may be obtained from the Registered Office of our Company i.e. "Chandra Bhagat Pharma Limited", the Lead Manager to the Issue i.e. Beeline Broking Limited, the Registrar to the Issue i.e. Link Intime India Private Limited. The application forms may also be downloaded from the website of BSE Limited i.e. www.bseindia.com. Application supported by Block Amount forms shall be available with designated branches of Self Certified Syndicate Banks, the list of which is available at websites of the Stock Exchange and SEBI.

AVAILABILITY OF PROSPECTUS: Investors are advised to refer to the Prospectus, and the Risk Factors contained therein, before applying in the issue. Full copy of the Prospectus is available on the website of SEBI (www.sebi.gov.in), website of the issuer Company (www.cbpharma.com), the website of the Lead Manager to the Issue (www.beelinebroking.com) and on the website of BSE Limited (www.bseindia.com). Investor should note that investment in equity shares involves high degree of risk. For details, investor should refer to and rely on the prospectus, including the section titled "Risk Factor" on page no. 15 of the prospectus, which has been filed with RoC.

APPLICATIONS SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors have to compulsorily apply through the ASBA process. ASBA has to be availed by all investors. Further as per SEBI Circular SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018, all Retail Individual Investors can also apply through Unified Payments Interface ("UPI"). The investor is required to fill the Application form and submit the same to the relevant SCSB or the Registered Brokers at Broker Center or the RTA or the CDP. The SCSB will block the amount in the account as per the authority contained in Application form and undertake other tasks as per the specified procedure. On Allotment, amount will be unblocked and account will be debited only to the extent required to be paid for Allotment of Equity Shares. Hence, there will be no need for refunds. For more details on the ASBA process, please refer to the section, "Issue Procedure" beginning on page no. 203 of the Prospectus.

Capitalized terms used herein and not specifically defined herein shall have the meaning given to such terms in the Prospectus.

| | |
|---|--|
| BANKER TO ISSUE AND SPONSOR BANK: AXIS BANK LIMITED (SEBI Regn No.: INB000000177 (Permanent Registration)) Address: Axis Bank Limited, Ground Floor Manec Plaza Opp. Central Plaza, Santacruz East, Mumbai - 400 098, Maharashtra; Office No.: (022) 26542007; Fax No.: (022) 26542007; Contact Person: Mr. Pankaj Mishra; Email: kalina.branchhead@axisbank.com; Web: www.axisbank.com; | On behalf of the Board of Directors FOR, CHANDRA BHAGAT PHARMA LIMITED Sd/- Hemant Chandravadan Bhagat Chairman cum Managing Director DIN: 00233530 |
|---|--|

ADDENDUM CUM CORRIGENDUM TO THE PROSPECTUS DATED JANUARY 23, 2020

This Addendum Cum Corrigendum should be read in conjunction with the Prospectus filed with the Registrar of Companies, Mumbai, Maharashtra ("ROC") on January 23, 2020:-
 1. On Page No 170 of the Prospectus, after the second para of Point No. 1 of Heading (A) Legal Notices Received, following para shall be added:
 As per books of Account of the Company, total amount outstanding is ₹ 13,92,360/-.
 2. On Page No 170 of the Prospectus, after the first para of Point No. 4 of Heading (A) Legal Notices Received, following para shall be added:
 As per books of Account of the Company, total amount outstanding is ₹ 39,13,247.32.
 3. On page No. 171 of the Prospectus, Pending Litigation No. 2(b), Next Hearing Date of Litigation Against Company, should be read as February 6, 2020 for past heard cases instead of December 27, 2019.
 4. On page No. 173 of the Prospectus, Pending Litigation No. 4, Next Hearing Date of Litigation Against Company, should be read as February 29, 2020 instead of January 18, 2020.
Chandra Bhagat Pharma Limited is proposing, subject to market condition and other considerations, a public issue of its Equity shares and has filed the prospectus with the registrar of companies, Mumbai, Maharashtra ("ROC"). The prospectus is available on the website of SEBI (www.sebi.gov.in), website of the Issuer Company (www.cbpharma.com), the website of the Lead Manager to the Issue (www.beelinebroking.com) and on the website of BSE Limited (www.bseindia.com). Investor should note that investment in equity shares involves high degree of risk. For details, investor should refer to and rely on the prospectus, including the section titled "Risk Factor" on page no. 15 of the prospectus, which has been filed with RoC, before making any investment decision.
 The equity shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within United States (as defined in regulations under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirement of the Securities Act. The equity shares are being offered and sold only outside the United States in offshore transaction in compliance with regulations under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

Shivalik Rasayan Limited
 Regd. Office: Village Kollhupani, P.O. Chandanwan, Dehradun - 248007
 (CIN: L24237UR1979PLC095041)
NOTICE
 NOTICE is hereby given pursuant to Regulation 29 & 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Meeting of Board of Directors of Shivalik Rasayan Limited will be held on Thursday, the 06th February, 2020, at 1506 Chiranjiv Tower, 43 Nehru Place New Delhi-110019, inter alia to consider, approve and take on record the un-audited Financial Results (Standalone & Consolidated) for the quarter ending on December 31, 2019.
 By order of the Board
 For Shivalik Rasayan Limited
 Sd/-
 Parul Choudhary
 Company Secretary
 Place: Delhi
 Dated: 30.01.2020

KITEX
Kitex Garments Limited
 (CIN: L18101KL1992PLC006528)
 Regd. Office: P. B. No. 5, Kozhikkambalam - 685952, Kochi, Kerala. Phone: 91 484 4142000; Fax: 91 484 286004
 E-mail: sec@kitexgarments.com, Website: www.kitexgarments.com
NOTICE
 Pursuant to Reg 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby given that a meeting of the Board of Directors of the Company will be held on Tuesday, February 11, 2020 at the Registered Office of the Company inter-alia to consider and take on record the un-audited financial results of the Company for the quarter and nine months ended December 31, 2019.
 The said Notice may be accessed on the Company's website at the link: www.kitexgarments.com and may also be accessed on the website of the stock exchanges at the www.nseindia.com and www.bseindia.com.
 For Kitex Garments Limited
 Sd/-
 Mithun B. Shenoy
 Company Secretary
 Kizhakkambalam
 January 29, 2020

Aster DM Healthcare Limited
 CIN: L85110KL2008PLC021703
 Aster Medcity, Kuttisahib Road, Near Kothad Bridge, South Chittoor P.O., Cheranalloor, Kochi, Kerala 682027, India
 T: 0484 6699228 E: cs@asterdmhealthcare.com
 W: www.asterdmhealthcare.com
NOTICE
 Notice is hereby given in compliance with the Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of Aster DM Healthcare Limited is scheduled to be held on Tuesday the 11th day of February 2020 inter-alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended 31st December 2019. For further details, please visit the website of the company at http://www.asterdmhealthcare.com/investors/.
 For Aster DM Healthcare Limited
 Sd/-
 Puja Aggarwal
 Company Secretary and Compliance Officer
 January 29, 2020
 Kochi, India.

Repro Home Finance Limited
 CIN: L65922TN2000PLC046655
 Registered Office: Repco Tower, No. 33, North Usman Road, T. Nagar, Chennai-600017
 Corporate Office: Third Floor, Alexander Square, Old No.34 & 35, New No.2, Sardar Patel Road, Guindy, Chennai-600032
 Ph: (044) - 4210 6650 Fax: (044) - 4210 6651;
 E-mail: cs@reprohome.com | Website: www.reprohome.com
NOTICE
 Notice is hereby given pursuant to Regulation 29 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, February 07, 2020, at the Corporate Office, inter alia to consider and approve the un-audited financial results of the Company for the quarter and nine month's period ended December 31, 2019.
 A copy of the Notice and the financial results on approval shall be available on the Company's website at www.reprohome.com and also on the website of the Stock Exchanges at www.nseindia.com and www.bseindia.com.
 For Repco Home Finance Limited
 Sd/-
 K.Prabhu
 Company Secretary
 Place: Chennai
 Date : 29.01.2020

Quick Heal
 Security Simplified
QUICK HEAL TECHNOLOGIES LIMITED
 CIN - L72200MH1995PLC091408
 Regd Office: Marvel Edge, Office No 7010, C & D, 7th Floor, Viman Nagar, Pune 411014, Maharashtra, India. Phone: +91 20 66813232.
 Website: www.quickheal.co.in
NOTICE
 Pursuant to Regulation 29 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, NOTICE IS HEREBY GIVEN that a Meeting of the Board of Directors of the Company will be held on Wednesday, February 05, 2020 at Marvel Edge, 7010 C & D, 7th Floor, Vimanagar, Pune, Maharashtra - 411 014 to inter alia consider and approve the Standalone and Consolidated un-audited financial Results of the Company for the quarter and nine months ended December 31, 2019.
 The outcome of the above meeting will be available on the website of the Company www.quickheal.co.in and also on the website of BSE Limited and National Stock Exchange of India Limited viz. www.bseindia.com and www.nseindia.com, respectively.
 Pursuant to the Company code to regulate, monitor and report trading by Directors, Promoters, Designated Persons of the Company, the Trading Window Close Period has commenced from January 01, 2020 and will end 48 hours after the financial results are made public on February 05, 2020.
 For Quick Heal Technologies Limited
 Sd/-
 Kailash Katkar
 Managing Director & CEO
 (DIN: 00397191)
 Pune, January 29, 2020

PUBLIC NOTICE
 IN HON'BLE NCLT, CHANDIGARH
 IN
 C.A. No. 936/2019
 C.P. (IB) No. 201/Chd/Hy/2018
 In the matter of
 STATE BANK OF INDIA
 VERSUS
 ...PETITIONER-FINANCIAL CREDITOR
 SRS LIMITED
 VERSUS
 ...RESPONDENT-CORPORATE DEBTOR
 CA 936/2019:
 ASHOK KUMAR GULLA,
 RESOLUTION PROFESSIONAL
 SRS LIMITED
 VERSUS
 ...APPLICANT - RESOLUTION PROFESSIONAL
 SRS WORLDWIDE FZC & ORS
 VERSUS
 ...RESPONDENTS
 The application registered as CA no. 936/2019 was filed by the Applicant - Resolution Professional. The matter was taken up by the Hon'ble Bench on 30.10.2019 and 07.01.2020 and wider order dated 30.10.2019, the Hon'ble Bench passed order for publication as a substitute mode of service where service of post could not be effected. Whereabouts of the following respondents are not known since the service could not be effected through ordinary post. The details of the respondents are as under:-
 1. SRS Worldwide FZC. Q-1-1-017, P.O. BOX, 8637 Registered with Sharjah Airport International Free Zone Authority (Sajf Zone) Sharjah (U.A.E.)
 2. M/s Vhaan Impex DC Unit No.30-01-374, Jewellery & Gemplex3, Plot No: DMCC-PH2-J&GPR, EXS, Dubai (UAE)
 3. SRS Shining Ornaments Limited. SRS Multiplex, City Centre, Sector-12 Faridabad, Haryana 121007
 4. Destiny Gems And Jewellers Private Limited H.No. 233, Sector-9 Faridabad, Haryana 121007
 5. Vinayak Jewellers C-9, Model Town III, Delhi, 110092
 6. Ashwani Singh F-263, 2nd Floor, Sector-57G Shalimar Agency, Sushant Lok Part-2, Gurgaon, Haryana
 7. Lucra Jewels Pvt Ltd, Kh No. -1092/601 H. No-245/37 East School Block Mandawai Delhi-110092
 8. Trustworthy Gems & Jewellery Pvt Ltd, Shop No. 4 On G/F At Fundan Singh Market, Main Karawal Nagar Chowk Opp DTC Bus Terminal New Delhi-110094
 9. Saubhagya Ornaments Pvt. Ltd. Shop No. 401, Fourth Floor, Property No. 1139 Kucha Mahajan, Chandni Chowk Delhi New Delhi 110006
 10. Logcal Jewellers Private Ltd. 1072, Kutcha Nawa, Chandni Chowk New Delhi - 110006
 11. Dr. Anil Jindal H. No. 538, Sector-14, Faridabad Also At: Jail Superintending Faridabad District Jail Tindal Road, Neemka Vilage Faridabad(Hr)-121002
 12. Mr. Sunil Jindal H. No. 538, Sector-14, Faridabad
 The above-mentioned respondents/persons are hereby informed that the C.A. No. 936/2019 in C.P. (IB) No. 201/Chd/Hy/2018 is pending before the Hon'ble NCLT Chandigarh and the next date of hearing is 06/02/2020 of the present case and the respondent hereby being informed to appear before the Hon'ble NCLT, Chandigarh on the next date of hearing i.e. 06.02.2020 at 10:00 A.M.

NOTICE
GEOJIT
 PEOPLE YOU PROSPER WITH
 Pursuant to Regulation 47 read with Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Thursday, 06th February, 2020 at the Registered Office of the Company to consider and to take on records inter alia, the Un-audited Financial Results of the company for the quarter ended 31.12.2019.
 The notice is available on the website of the company (www.geojit.com) as well as on the website of BSE Limited (www.bseindia.com) and the National Stock Exchange of India Limited (www.nseindia.com).
 For Geojit Financial Services Ltd.
 Sd/-
 Liju K Johnson
 Company Secretary
 Date : 30.01.2020
 Place : Kochi
 Geojit Financial Services Ltd.
 Reg. Office: 34/659-P, Civil Line Road, Padivattom, Kochi, Kerala - 682024.
 CIN: L67120KL1994PLC009403. Ph: 0484-2901000. Fax: 0484-2979695.
 Email: mailus@geojit.com, www.geojit.com.

AIR INDIA ASSETS HOLDING LIMITED
 GLOBAL INVITATION FOR EXPRESSION OF INTEREST FOR PROPOSED STRATEGIC SALE AND TRANSFER OF MANAGEMENT CONTROL OF AIR INDIA AIR TRANSPORT SERVICES LIMITED BY AIR INDIA ASSETS HOLDING LIMITED
 This is with reference to the Preliminary Information Memorandum issued by Air India Assets Holding Limited ("AIHL") on 12th February, 2019, for inviting Expression of Interest for the proposed strategic sale of Air India Air Transport Services Limited ("AIATSL"), followed by Corrigendum, Second Corrigendum, Third Corrigendum, Fourth Corrigendum, Fifth Corrigendum, Sixth Corrigendum, Seventh Corrigendum, Eighth Corrigendum, Ninth Corrigendum, Tenth Corrigendum and Eleventh Corrigendum issued on 5th March 2019, 26th March 2019, 24th April 2019, 25th May 2019, 25th June 2019, 25th July 2019, 26th August 2019, 24th September 2019, 25th October 2019, 28th November 2019 and 27th December 2019 respectively.
 It is hereby informed that the cited process for the proposed strategic sale of AIATSL stands cancelled, and AIHL will reinitiate the process for the proposed strategic sale of AIATSL, in due course.

Vaibhav Global Limited
 Regd. Off: K-68, Fateh Tiba, Adarsh Nagar, Jaipur-302004
 Phone: 91-141-2601020; Fax: 91-141-2605077; CIN: L36911RJ1989PLC004945
 Email: investor_relations@vaibhavglobal.com; Website: www.vaibhavglobal.com
NOTICE OF RECORD DATE FOR THE PURPOSE OF INTERIM DIVIDEND
 NOTICE is hereby given that pursuant to provisions of Section 91 of the Companies Act, 2013 read with Rules made thereunder and in accordance with SEBI Regulations, Record Date shall be 30th February, 2020 for the purpose of Interim Dividend declared by the Board in its meeting held on 29th January, 2020. The Interim Dividend shall be credited/dispensed on or before 28th February, 2020.
 SEBI has stipulated that all listed companies shall use approved mode of payment viz direct credit, NEFT, RTGS, "payable-at-par" warrants/ cheques etc. for the purpose of making payments to the shareholders. All the shareholders are requested to immediately update their Bank Account No., if the same has not been updated with the Company's share transfer agent or the depository participant, as the case may be.
 Please keep your updated email ID registered with the Company/ Depository Participant to receive timely communication.
 This notice may be accessed on Company's website i.e www.vaibhavglobal.com and also on Stock Exchange websites i.e www.bseindia.com & www.nseindia.com.
 For Vaibhav Global Limited
 Sd/-
 Sushil Sharma (Company Secretary)
 Place : Jaipur
 Date: 29th January, 2020
 FCS: 6535

xelp
Xelpmoc Design and Tech Limited
 CIN: L72200KA2015PLC082873,
 Registered Office: #17, 4th Floor, Agies Building, 1st 'A' cross, 5th Block, Koramangala, Bengaluru - 560034, Tel. No: 080 4370 8360;
 E-mail: vaishali.kondhar@xelpmoc.in; Website: www.xelpmoc.in
 Notice is hereby given pursuant to Regulation 29 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, February 05, 2020 at 91 Springboard, B-Wing, 5th Floor, Akruti Trade Center, Andheri (East), Mumbai - 400093 inter-alia, to consider, approve and to take on record the Unaudited Financial Results (Standalone and Consolidated) of the Company along with the Limited Review Report for the 3rd quarter and nine months ended December 31, 2019 of the Company. This information is also available on the Company's website (www.xelpmoc.in) and also available on the website(s) of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com).
 By Order of the Board
 For Xelpmoc Design and Tech Limited
 Sd/-
 Vaishali Kondhar
 Company Secretary
 Date :- January 29, 2020
 Place : Bengaluru

RR SHRAMIK
RAM RATNA WIRES LIMITED
 (CIN: L31300MH1992PLC067802)
 Regd. Office: Ram Ratna House, Oasis Complex, P.B.Marg, Worli, Mumbai 400 013 • Tel: +91 - 22 - 2494 9009/ 2492 4144
 Email Id: investorrelations@rrglobal.com • Website: www.rsrshramik.com
NOTICE
 Notice is hereby given pursuant to Regulation 29 read with Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 12th February, 2020, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 31st December, 2019.
 The said notice may also be accessed on the Company's website at www.rsrshramik.com and on the website of the Stock Exchange at www.bseindia.com
 For Ram Ratna Wires Limited
 Sd/-
 Saurabh Gupta
 Company Secretary
 Place : Mumbai
 Dated: 29th January, 2020

LOKESH MACHINES LTD
 Regd. Off: Regd. Office: B-29, EEEI STAGE-II, BALANAGAR, HYDERABAD- 500037
 Ph: 040-23079310, E-mail: coseq@lokeshmachines.com Website: www.lokeshmachines.com
 CIN: L29219TG1983PLC004319
TRANSFER OF EQUITY SHARES TO THE INVESTOR EDUCATION AND PROTECTION FUND (IEPF)
 Members are hereby informed that in terms of Section 124 of the Companies Act, 2013 and IEPF Rules, 2016 as amended including any statutory modifications thereof, equity shares of the Company, in respect of which dividend entitlements have remained unclaimed or unpaid for seven consecutive financial years or more, are required to be transferred by the Company to the Investor Education and Protection Fund (IEPF).
 It is notified from the records that certain Members of the Company have not cashed their dividend warrants and their dividends have remained unpaid /unclaimed for seven consecutive years from the financial year 2010-11 and 2011-12. The Company has uploaded full details of such members whose shares are due for transfer to IEPF on its website, viz.

